FilipJankuMDPhD

Oncology • Houston, TX

Associate Professor, Center Medical Director

Join to view full profile

Dr. Janku is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Janku's full profile

Already have an account?

Office
1515 Holcombe Blvd
Houston, TX 77030
Phone+1 713-745-9200

Education & Training

Charles University in Prague Faculty of MedicineClass of 1999

Certifications & Licensure

TX State Medical License 2013 - 2025
OK State Medical License 2020 - 2021
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

Sirolimus and Cetuximab in Advanced Malignancies Start of enrollment: 2009 Jul 01
Completed
Phase 1
Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies Start of enrollment: 2009 Nov 01
Completed
Phase 1
Docetaxel and Sirolimus in Patients With Advanced Malignancies Start of enrollment: 2010 Jan 01
Completed
Phase 1
Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer Start of enrollment: 2010 Mar 01
Active, not recruiting
Phase 1
Lapatinib With Sirolimus or Metformin Start of enrollment: 2010 Mar 01
Completed
Phase 1
Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance Start of enrollment: 2010 Sep 07
Completed
Phase 1
Sirolimus or Vorinostat and Hydroxychloroquine in Advanced Cancer Start of enrollment: 2011 Apr 28
Completed
Phase 1
A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors Start of enrollment: 2012 Mar 01
Completed
Phase 1
Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations Start of enrollment: 2012 Feb 06
Completed
Phase 1
Everolimus and Anakinra or Denosumab in Treating Participants With Relapsed or Refractory Advanced Cancers Start of enrollment: 2012 Jun 19
Completed
Phase 1
Study of Vemurafenib, Carboplatin, and Paclitaxel Start of enrollment: 2012 Jul 09
Completed
Phase 1
Dabrafenib and Pazopanib Hydrochloride in Treating Patients With Advanced Malignant Tumors Start of enrollment: 2012 Nov 19
Completed
Phase 1
Ipilimumab and Lenalidomide in Advanced Cancer Start of enrollment: 2013 Mar 01
Completed
Phase 1
Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies Start of enrollment: 2013 Mar 01
Completed
Phase 1, Phase 2
Safety Study of Intratumoral Injection of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies Start of enrollment: 2013 Oct 01
Completed
Phase 1
BP31510 (Ubidecarenone,USP) Nanosuspension for Intravenous Injection to Patients With Solid Tumors Start of enrollment: 2013 Oct 01
Completed
Phase 1
Profile Related Evidence to Determine Individualized Cancer Therapy (PREDICT) Program in Advanced Cancer Patients Start of enrollment: 2010 Sep 27
Recruiting
Study of FF-10502-01 in Patients With Advanced Solid Tumors and Lymphomas Start of enrollment: 2016 Jan 01
Completed
Phase 1, Phase 2
Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT Start of enrollment: 2018 Jul 10
Active, not recruiting
Phase 1
Dabrafenib and Trametinib in Treating Patients With Erdheim Chester Disease With BRAF V600 Mutations Start of enrollment: 2019 Jan 04
Withdrawn
Phase 2
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions Start of enrollment: 2019 Jun 28
Recruiting
Phase 1, Phase 2
Talabostat and Pembrolizumab for the Treatment of Advanced Solid Cancers Start of enrollment: 2020 Mar 19
Active, not recruiting
Phase 2
Study of SO-C101 and SO-C101 in Combination With Pembro in Adult Patients With Advanced/Metastatic Solid Tumors Start of enrollment: 2019 Jun 13
Active, not recruiting
Phase 1
Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N) Start of enrollment: 2016 Feb 25
Active, not recruiting
Phase 2
Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotocol P) Start of enrollment: 2016 Feb 25
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

Predictive Significance of Combined Plasmatic Detection of BRAF Mutations and S100B Tumor Marker in Early-Stage Malignant Melanoma.
Jiri Polivka, Mohamed A Gouda, Mahyar Sharif, Martin Pesta, Helen Huang
Cancer Medicine. 2024-10-01
A Phase I Study of the Oral Dual-Acting Pan-PI3K/mTOR Inhibitor Bimiralisib in Patients with Advanced Solid Tumors.
Filip Janku, Grace M Choong, Mateusz Opyrchal, Afshin Dowlati, Cinta Hierro
Cancers. 2024-03-13
1 citations
Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid M...
Vivek Subbiah, Niamh Coleman, Sarina A Piha-Paul, Apostolia M Tsimberidou, Filip Janku
Cancer Research Communications. 2024-02-12

Journal Articles

Phase 1 Study of AMG 337, a Highly Selective Small-Molecule MET Inhibitor, in Patients with Advanced Solid Tumors
Eunice L Kwak, Filip Janku, David S Hong, Clinical Cancer Research
Characteristics and Outcomes of Patients with Advanced Sarcoma Enrolled in Early Phase Immunotherapy Trials
David S Hong, Neeta Somaiah, Anthony Conley, Shreyaskumar Patel, Filip Janku, Aung Naing, Kenneth Hess, Robert Benjamin, BioMed Central

Lectures

MEK Inhibition with Trametinib in Patients with Non-Langerhans Cell Histiocytosis
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Phase 1/2 trial of FF-10502-01, a pyrimidine antimetabolite, in patients with advanced cholangiocarcinoma and solid tumors.
2019 ASCO Annual Meeting - 6/1/2019
Phase 1/2 precision medicine study of the next-generation BRAF inhibitor PLX8394.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
A phase I study of LXH254 in patients (pts) with advanced solid tumors harboring MAPK pathway alterations.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Join now to see all

Press Mentions

As Biotech Debates Vaccine Mandates, One CEO Tries to Convince the 3% That Got AwayAugust 11th, 2021
Chutes & Ladders—FDA Nod for Biogen's Aduhelm Sees Trio of AdComm Members Hit the ExitJune 11th, 2021
Monte Rosa Therapeutics Expands Leadership Team with Appointment of Filip Janku, M.D., Ph.D., as Chief Medical OfficerJune 10th, 2021
Join now to see all

FilipJankuMDPhD

Dr. Janku is on Doximity

Education & Training

Certifications & Licensure

Clinical Trials

Publications & Presentations

Press Mentions

Viewing the full profile is available to verified healthcare professionals only.